NewAI-Powered Evidence-Based Clinical Research Assistant

Never miss a breakthrough that could save lives 

An AI agent that finds the most relevant studies for you and your patients — grounded in evidence-based medicine, personalized to your clinical context.

See how it works

Clinicians are drowning in research they can't keep up with

0+

medical papers published daily

0

years average delay for breakthroughs to reach patients

0

American lives lost annually to outdated practices

A patient suffered for 10 years with treatment-resistant depression. The Stanford SAINT protocol achieved 90% remission in 5 days — but her doctor never knew it existed.

Your Personalized Evidence Feed

  • Thousands of papers filtered to what matters to you
  • AI-summarized TL;DR on every card
  • Swipe through cards to explore your daily evidence
  • Learns from your behavior — gets smarter every day
  • Auto-evaluates study rigor and trustworthiness
Psychiatry
BreakthroughHigh Impact

Stanford's 5-Day Brain Stimulation Protocol Achieves 90% Remission

Am J Psychiatry · 2020

A revolutionary 5-day protocol using fMRI-guided TMS achieved 90.5% remission in treatment-resistant depression patients.

TMSDepressionNeuromodulation
Cardiology
New This WeekGuideline Update

GLP-1 Receptor Agonists Reduce Major Adverse Cardiac Events by 14%

NEJM · 2025

Large-scale trial demonstrates semaglutide significantly reduces MACE in patients with established cardiovascular disease.

GLP-1MACESemaglutide
Oncology
Clinically Actionable

CAR-T Therapy Shows Durable Remission in Relapsed Lymphoma

Lancet Oncol · 2025

5-year follow-up confirms sustained complete response in 40% of patients with relapsed/refractory large B-cell lymphoma.

CAR-TLymphomaImmunotherapy
Pediatrics
High Impact

Early Peanut Introduction Reduces Allergy Risk by 77%

NEJM · 2024

LEAP follow-up study confirms lasting protection from peanut allergy with early introduction in high-risk infants.

AllergyPreventionPediatrics
Neurology
New This Week

Lecanemab Slows Cognitive Decline by 27% in Early Alzheimer's

NEJM · 2025

Phase 3 confirms anti-amyloid antibody moderately slows progression in early-stage Alzheimer's disease over 18 months.

Alzheimer'sAnti-amyloidPhase 3
Ask question about this paper

Open any paper. Get the full picture in seconds.

  • AI-generated lay summary
  • Key figure and table digest from the paper
  • Structured key breakpoints: research question, data, method, result, and clinical implication
  • Follow-up questions answered in context with citations
Feed informs AI ⇄ AI informs Feed

Your AI Clinical Agent

  • Persistent memory across sessions
  • Every claim grounded with citations
  • Understands your clinical context
  • Learns from your feed interactions too
  • Transparent reasoning — watch it search, screen, and synthesize
S

SciSpark AI

Remembers your context

ONLINE
Ask a follow-up question...

Intelligence you can trust

Evidence-Based

Auto-evaluates scientific rigor, methodology quality, and clinical trustworthiness

Precision-Personalized

Tailored to your specialty, patients, and clinical context

Always Up-to-Date

Continuously tracking latest research worldwide, new studies indexed as they publish

Self-Improving

Feed behavior informs AI, AI conversations refine feed — the flywheel gets smarter

How It Works

1

Tell us your focus

Set your specialty, interests, and clinical questions

2

Get your daily digest

AI curates and summarizes the evidence that matters to you

3

Ask anything

Dive deeper with AI Q&A grounded in cited sources

Built for Every Clinician

Attending Physicians

Balancing 30+ patients a week, I need to catch new treatments and updated guidelines — without reading 50 papers.

Residents & Fellows

Staying current across multiple rotations with limited time. SciSpark keeps me informed without the overwhelm.

Clinical Researchers

Tracking breakthroughs across adjacent fields and disciplines — I can't afford to miss what's happening outside my niche.

Frequently Asked Questions

Better evidence. Better care.

Join hundreds of clinicians getting early access to SciSpark.